Full-year report on Innate Pharma's liquidity contract with Gilbert Dupont
Upcoming investor conferences
Fourth clinical trial opened with monalizumab (IPH2201)
Number of shares and voting rights of Innate Pharma as at December 7, 2015
First patient dosed in Phase I trial of IPH4102
New combination trial with lirilumab in hemato-oncology
Third Quarter 2015 Report
Innate Pharma receives development milestone payment from Bristol-Myers Squibb
Opening of the Phase I/II trial of IPH2201 in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia
First patient treated in phase I/II trial with IPH2201 in ovarian cancer
